Literature DB >> 981

Studies of the pain produced by mafenide acetate preparations in burns.

H N Harrison, J M Shuck, E Caldwell.   

Abstract

In a double-blind triple cross-over clinical study, 37 patients were exposed to several formulations of mafenide acetate (Sulfamylon Cream) and their pain responses were recorded and converted to a semiquantitative pain index. The 11.2% concentration in cream was two to three times more painful than the 5% concentration. Hypertonicity and not the pH level appears to be the cause of the pain produced by the high (11.2%) concentration. The tonicity of the cream carrier and 11.2% mafenide acetate are 1,080 mOsm/kg and 1,100 mOsm/kg, respectively, for a total of 2,180 mOsm/kg. The carrier cream without glycerol and a 5% concentration of mafenide cream were much less painful than the 11.2% concentration of mafenide. Both afforded a great deal of relief to the patients who received the medications.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 981     DOI: 10.1001/archsurg.1975.01360180016003

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Antibiotic eluting clay mineral (Laponite®) for wound healing application: an in vitro study.

Authors:  M Ghadiri; W Chrzanowski; R Rohanizadeh
Journal:  J Mater Sci Mater Med       Date:  2014-07-16       Impact factor: 3.896

2.  A simple cost-saving measure: 2.5% mafenide acetate solution.

Authors:  Amir Ibrahim; Shawn Fagan; Tim Keaney; Karim A Sarhane; Derek A Hursey; Philip Chang; Rob Sheridan; Colleen Ryan; Ronald Tompkins; Jeremy Goverman
Journal:  J Burn Care Res       Date:  2014 Jul-Aug       Impact factor: 1.845

Review 3.  Honey: a potential therapeutic agent for managing diabetic wounds.

Authors:  Fahmida Alam; Md Asiful Islam; Siew Hua Gan; Md Ibrahim Khalil
Journal:  Evid Based Complement Alternat Med       Date:  2014-10-15       Impact factor: 2.629

Review 4.  Review of History of Basic Principles of Burn Wound Management.

Authors:  Hyunjin Kim; Seongmee Shin; Donghoon Han
Journal:  Medicina (Kaunas)       Date:  2022-03-07       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.